Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

21
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
21
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

269
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
269
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

38
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
38
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.9K
Clinical Trials01:16

Clinical Trials

9.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.8K
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

506
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
506

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Whether to make decisions «on the fly» regarding treatment for SARS-CoV-2 infection].

Revista clinica espanola·2024
Same author

Current approach to skin and soft tissue infections. Thinking about continuity of care.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2023
Same author

Recommendations on the use of azole antifungals in hematology-oncology patients.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2023
Same author

Norovirus infection as a model of chronic or recurrent infection in common variable immunodeficiency.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2022
Same author

Current management of CMV infection in cancer patients (solid tumors). Epidemiology and therapeutic strategies.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2022
Same author

Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2022

Related Experiment Video

Updated: Oct 18, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K

Tedizolid: new data and experiences for clinical practice.

M Salavert Lletí1, V García-Bustos, L Morata Ruiz

  • 1Miguel Salavert, Unidad de Enfermedades Infecciosas. Hospital Universitario y Politécnico La Fe, Valencia. Spain. salavert_mig@gva.es.

Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|October 2, 2021
PubMed
Summary

Tedizolid demonstrates a favorable safety profile for long-term use in off-label infections, including osteoarticular and mycobacterial cases. It offers a lower interaction risk than linezolid and shows promise in treating Gram-positive bacterial pneumonia.

More Related Videos

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

7.9K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.1K

Related Experiment Videos

Last Updated: Oct 18, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

7.9K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.1K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Medicine

Background:

  • Tedizolid is an oxazolidinone antibiotic.
  • Recent clinical data on tedizolid's efficacy and safety are emerging.
  • Comparative safety and efficacy against linezolid are of clinical interest.

Purpose of the Study:

  • To review recent clinical data on tedizolid's applications.
  • To highlight tedizolid's safety and tolerance in long-term therapy.
  • To explore novel therapeutic uses and combinations of tedizolid.

Main Methods:

  • Review of studies published within the last 18 months.
  • Analysis of clinical data on tedizolid's safety and efficacy.
  • Inclusion of in vitro and in vivo study findings.

Main Results:

  • Tedizolid exhibits improved tolerance and safety in long-term treatment for off-label indications.
  • Lower risk of hazardous interactions compared to linezolid.
  • Combination therapy with rifampicin shows favorable outcomes.
  • Potential efficacy in nosocomial pneumonia caused by Gram-positive bacteria.

Conclusions:

  • Tedizolid is a safe and effective option for long-term therapy in specific off-label infections.
  • Its safety profile is advantageous compared to linezolid.
  • Combination with rifampicin and potential use in pneumonia warrant further investigation.